Phosphatidylserine for Memory: Positive Older Trials, a Null Soy Trial, and Formulation Confusion

Bottom line: Phosphatidylserine has a long human cognition literature, but it is messier than the familiar "clinically proven memory supplement" claim suggests. Older trials were positive, a later soy-derived PS trial was null, and newer positive studies often use modified or combined formulations.

The older evidence looked promising

Randomized trials in the early 1990s reported improvements in memory or cognitive/behavioral measures among older adults with age-associated impairment.[1][2]

These studies helped establish phosphatidylserine's reputation.

The formulations often used bovine-cortex-derived phosphatidylserine.

That matters because modern supplements are generally sourced differently.

The soy-derived trial was negative

A 2001 randomized controlled trial assigned 120 older adults with memory complaints to placebo, 300 mg/day soy-derived phosphatidylserine, or 600 mg/day.[3]

The primary outcomes involved delayed recall and recognition.

No significant treatment differences were found on the primary or other cognitive outcomes.[3]

That negative result is important because it tested a form closer to many later commercial products.

Later trials complicate attribution

A 2010 randomized trial tested a phosphatidylserine preparation containing omega-3 fatty acids in older adults with memory complaints.[4]

Some memory outcomes improved.

But PS-DHA is not identical to isolated phosphatidylserine.

When a formulation chemically incorporates or combines other bioactive components, the result belongs to that formulation unless evidence shows equivalence.

Why source history matters

Earlier bovine-derived products and modern soy- or marine-derived phosphatidylserine differ in origin and sometimes fatty-acid composition.

It is not safe to assume that every historical positive trial maps directly onto a modern capsule.

That is a classic example of why an ingredient database needs formulation-level evidence rather than a single pooled "works/doesn't work" verdict.

What about stress claims?

Phosphatidylserine has also been studied in stress-response experiments, sometimes alone and sometimes with omega-3 fatty acids.

Those results are mixed and often involve small samples.

They should remain separate from age-related cognition evidence.

What evidence would resolve the formulation question?

The cleanest answer would come from modern head-to-head or independently replicated trials that identify the phosphatidylserine source and fatty-acid composition rather than treating every PS preparation as interchangeable. That would show whether the older positive findings reflect phosphatidylserine itself, a particular source, or a formulation-specific effect.

Primary outcomes matter as well. Memory complaints can be measured with many tests, and a positive secondary task does not cancel a neutral prespecified primary endpoint. Future trials should make that hierarchy easy to see and should report effect sizes rather than only whether a threshold for statistical significance was crossed.

The population boundary also needs to remain intact. Age-associated memory complaints, diagnosed dementia, stress-response studies, and healthy-young-adult nootropic use are different questions. Evidence from one group should not automatically raise confidence for the others. The same rule applies to duration: a short cognitive-test change cannot establish protection against long-term cognitive decline or dementia.

Verdict

Phosphatidylserine has limited, mixed human evidence for memory, with meaningful positive historical trials and meaningful negative evidence.

The biggest interpretive issue is formulation identity: old bovine PS, soy PS, and PS-DHA should not be treated as one interchangeable intervention.